Obara, Wataru Iwate Medical University
Kanehira, Mitsugu Iwate Medical University
Katagiri, Toyomasa Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Kato, Renpei Iwate Medical University
Kato, Yoichiro Iwate Medical University
Takata, Ryo Iwate Medical University
cancer peptide vaccine therapy
renal cell carcinoma
Use of peptide-based vaccines as therapeutics aims to elicit immune responses through antigenic epitopes derived from tumor antigens. Peptide-based vaccines are easily synthesized and lack significant side-effects when given in vivo. Peptide-based vaccine therapy against several cancers including urological cancers has made progress for several decades, but there is no worldwide approved peptide vaccine. Peptide vaccines were also shown to induce a high frequency of immune response in patients accompanied by clinical efficacy. These data are discussed in light of the recent progression of immunotherapy caused by the addition of immune checkpoint inhibitors thus providing a general picture of the potential therapeutic efficacy of peptide-based vaccines and their combination with other biological agents. In this review, we discuss the mechanism of the antitumor effect of peptide-based vaccine therapy, development of our peptide vaccine, recent clinical trials using peptide vaccines for urological cancers, and perspectives of peptide-based vaccine therapy.
Japanese Cancer Association
© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
|DOI (Published Version)|
|URL ( Publisher's Version )|
cas_109_3_550.pdf 1010 KB
Institute of Advanced Medical Sciences